Insights

Innovative Hydrogel Platform GelMEDIX's proprietary photo-crosslinked hydrogel technology offers unique opportunities for partners interested in advanced bioadhesives and regenerative materials, especially within ophthalmology and regenerative medicine markets.

Focus on Vision Restoration The company's flagship program targeting macular degeneration presents a strong market opportunity for healthcare providers and biotech firms seeking to expand into ophthalmic regenerative therapies.

Funding and Revenue Potential With recent funding of nearly $2 million and current revenues between $1 million and $10 million, GelMEDIX is positioned for potential growth, inviting investment and collaboration from stakeholders in biotech and regenerative medicine.

Tech-Driven Development Utilizing modern cloud and web technologies, GelMEDIX maintains an innovative R&D environment, which may appeal to tech-focused partners interested in cutting-edge biotech platforms.

Collaborative Academic Roots Founded from strong academic collaborations with Harvard and UCLA, the company offers opportunities for partnerships with academic institutions and research organizations aiming to advance regenerative therapies.

GelMEDIX Tech Stack

GelMEDIX uses 8 technology products and services including Google Cloud CDN, JSON-LD, React, and more. Explore GelMEDIX's tech stack below.

Google Cloud CDN

Content Delivery Network

JSON-LD

Javascript Frameworks

React

Javascript Frameworks

Lodash

Javascript Libraries

Envoy

Load Balancers

WebsiteBuilder

Page Builders

Priority Hints

Performance

HTTP/3

Web & Portal Technology

GelMEDIX Email Formats	Example	Percentage
First@gelmedix.com	John@gelmedix.com	43%
FirstLast@gelmedix.com	JohnDoe@gelmedix.com	7%
First@gelmedix.com	John@gelmedix.com	43%
FirstLast@gelmedix.com	JohnDoe@gelmedix.com	7%

GelMEDIX Email Formats

Example

Percentage

First@gelmedix.com

John@gelmedix.com

43%

FirstLast@gelmedix.com

JohnDoe@gelmedix.com

First@gelmedix.com

John@gelmedix.com

43%

FirstLast@gelmedix.com

JohnDoe@gelmedix.com

Frequently Asked Questions

What is GelMEDIX's official website and social media links?

GelMEDIX's official website is gelmedix.com and has social profiles on LinkedIn Crunchbase.

What is GelMEDIX's SIC code NAICS code?

GelMEDIX's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does GelMEDIX have currently?

As of December 2025, GelMEDIX has approximately 13 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Executive Officer: M. C.Senior Scientist: N. V.Senior Scientist: A. C.. Explore GelMEDIX's employee directory with LeadIQ.

What industry does GelMEDIX belong to?

GelMEDIX operates in the Biotechnology Research industry.

What technology does GelMEDIX use?

GelMEDIX's tech stack includes Google Cloud CDNJSON-LDReactLodashEnvoyWebsiteBuilderPriority HintsHTTP/3.

What is GelMEDIX's email format?

GelMEDIX's email format typically follows the pattern of First@gelmedix.com. Find more GelMEDIX email formats with LeadIQ.

How much funding has GelMEDIX raised to date?

As of December 2025, GelMEDIX has raised $1.9M in funding. The last funding round occurred on Mar 26, 2024 for $1.9M.

When was GelMEDIX founded?

GelMEDIX was founded in 2020.

GelMEDIX

Q: What is GelMEDIX's official website and social media links?

GelMEDIX's official website is gelmedix.com. GelMEDIX has social profiles on LinkedIn.

Q: How many employees does GelMEDIX have currently?

GelMEDIX has approximately 13 employees.

Q: What technology does GelMEDIX use?

GelMEDIX's tech stack includes Priority Hints, Module Federation, JSON-LD, Bootstrap, X-Content-Type-Options.

Biotechnology ResearchMassachusetts, United States11-50 Employees

GelMEDIX Inc. is an early-stage biotechnology company leveraging its hydrogel platform to develop ocular and regenerative therapies that can restore vision.



GelMEDIX was founded after multiple years of fruitful academic collaboration between our co-founders Reza Dana (Mass. Eye And Ear, Harvard Med. School) and Nasim Annabi (UCLA). 


Our proprietary photo-crosslinked hydrogels uniquely enable
bioadhesion, tissue regeneration, tunable mechanics, and therapeutic loading across modalities from small molecules to cell and gene therapies.



Our lead program is an integrated hydrogel cell therapy designed to
restore vision for macular degeneration patients with Dry AMD and GA.

Insights

Similar companies to GelMEDIX

Athersys

GelMEDIX Tech Stack

Media & News

GelMEDIX's Email Address Formats